Allogeneic hematopoietic stem cell transplantation for the treatment of acute myeloid leukemia with primary thrombocytosis: three cases report and literatures review
10.3760/cma.j.issn.0253-2727.2017.10.011
- VernacularTitle: 异基因造血干细胞移植治疗原发性血小板增多症转化的急性髓系白血病三例报告并文献复习
- Author:
Xiangping ZONG
1
;
Lin TANG
;
Jiannong CEN
;
Suning CHEN
;
Aining SUN
;
Depei WU
Author Information
1. Jiangsu Institute of Hematology, the First Affiliated Hospital of Soochow University, Suzhou 215006, China
- Publication Type:Journal Article
- Keywords:
Thrombocythemia, essential;
Leukemia, myeloid, acute;
Hematopoietic stem cell transplantation
- From:
Chinese Journal of Hematology
2017;38(10):883-886
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the characteristics of the essential thrombocythemia (ET) cases transformed to the acute myeloid leukemia (AML) and the role of allogeneic hematopoietic stem cell transplantation (allo-HSCT) in the treatment of this disease.
Methods:The clinical and laboratory characteristics of 3 ET cases before and after transformation and after allo-HSCT were retrospectively analyzed, meanwhile the related literatures were reviewed and discussed.
Results:Case 1 was a male patient of 44 years old, whose PLT was 500×109/L when firstly diagnosed ET. After 3 years the disease progressed into myelodysplastic syndrome (MDS) while WT1 expression increased from 77 (first visit) to 13 171 copies/10 000 ABL copies, at the same time chromosome changed dramatically. During the period of decitabine treatment the disease processed into AML. Case 2 was a male of 58 years old whose PLT was 2 100×109/L when firstly diagnosed ET. The disease progressed to AML after 9 years, whose WT1 expression increased from 130 (first visit) to 3 222 copies/10 000 ABL copies, and he relapsed shortly after intensive chemotherapy. Case 3 was a male of 60 years old whose PLT was 900×109/L when firstly diagnosed ET. The disease progressed to AML after 5 years, whose WT1 increased from 56 (first visit) to3 696 copies/10 000 ABL copies. Moreover leukemia spread to central nervous system (CNS) during chemotherapy. Before allo-HSCT, cases 1 did not achieve remission; case 2 relapsed after a short time of remission and case 3 transferred to CNS leukemia. All of the 3 cases underwent allo-HSCT successfully, and they all achieved completely remission, whose chromosome and gene mutation recovered negative. At the same time, CNS leukemia of case 3 disappeared. The median WT1 decreased to 50 copies/10 000 ABL copies. There was no severe complication during the median time of 5 months after allo-HSCT.
Conclusions:The patients transformed to AML had poor prognosis, allo-HSCT was the only method that can cure the disease now.
